AzTrials
AzTrials

Postural Orthostatic Tachycardia SyndromeCASA-POTSNCT05924646

CAlgary SAlt for POTS

A study testing Sodium Chloride Capsules and Microcystalline Cellulose Capsules in people with Postural Orthostatic Tachycardia Syndrome, run by University of Calgary at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend ~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. Read more about this study

Who is it for?
Ages 18 to 60 years
What is being tested?
Sodium Chloride Capsules and Microcystalline Cellulose Capsules
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteCanada
Study dates
7 May 2024to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Physician Diagnosis of POTS as defined by the CCS Consensus Statement and as follows:
  • Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing.
  • Absence of orthostatic hypotension (>20/10 mmHg decrease) within 3 minutes standing.
  • Chronic orthostatic symptoms that improve with recumbence.
  • Age 18-60 years old.
  • Ability to attend the Calgary Autonomic Research Clinic in Calgary.
  • Resident of Canada

Who cannot join

  • Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease)
  • Participants with somatization or severe anxiety symptoms will be excluded
  • Pregnant (self-reported)
  • Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest.
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies
  • Fludrocortisone use (due to effects on renal Na+ handling)
  • Patients who have received IV saline in the 2 months preceding the study or who plan to receive it during the course of the study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Satish R Raj, MD MSCI contact

4032106152

autonomic.research@ucalgary.ca

Tanya Siddiqui, MBBS contact

autonomic.research@ucalgary.ca

Canada1 site, 1 recruiting
  • University of Calgary

    Calgary, Alberta, T2N 4Z6

    Satish R Raj, MD, MSCI, 403-210-6152, autonomic.research@ucalgary.ca

    Recruiting

Other trials in Canada

About this study

Official title: CAlgary SAlt for Postural Orthostatic Tachycardia Syndrome Study

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend ~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.

Read the detailed description

Background and Rationale:

Postural Orthostatic Tachycardia Syndrome (POTS) is a form of autonomic cardiovascular disease, primarily in women, that is often disabling. The investigators and others have found that many patients with postural tachycardia have decreased plasma volume. Current POTS guidelines recommend ~10 g of salt and 2-3 L of fluid per day. In a proof of concept dietary salt study, the investigators recently showed 6 days of a high salt diet (300 mEq/d), compared to a low salt diet, increases plasma volume, reduced standing plasma norepinephrine, and reduced HR. The high salt diet reduced the median orthostatic tachycardia by 14 bpm. Currently there is only evidence showing the benefits of supplemental salt-intake over one week. It is unknown whether the increased blood volume from high dietary salt intake will persist over several weeks, or if an "escape mechanism" will reduce blood volumes back to baseline levels. This longer-term clinical trial of high dietary salt and water will address this "escape mechanism" and ongoing dietary compliance in POTS.

Research Question \& Objectives:

Primary Hypothesis: The primary hypothesis is that after 6 weeks of a moderate dietary salt plus additional salt diet, the upright HR will be lower than after 6 weeks on a moderate dietary salt alone diet.

Secondary hypotheses: The secondary hypotheses include:

  • Symptoms evaluated using the VOSS symptom score after 6 weeks of a moderate dietary salt plus additional salt diet will be reduced compared to after 6 weeks of a moderate dietary salt alone diet;
  • Upright stroke volume after 6 weeks of a moderate dietary salt plus additional salt diet will be increased compared to after 6 weeks of a moderate dietary salt alone diet;
  • Blood volume after 6 weeks of a moderate dietary salt plus additional salt diet will be increased compared to after 6 weeks of a moderate dietary salt alone diet;
  • Upright plasma catecholamines after 6 weeks of a moderate dietary salt plus additional salt diet will be increased compared to after 6 weeks of a moderate dietary salt alone diet;
  • Quality of life after 6 weeks of a moderate dietary salt plus additional salt diet will be increased compared to after 6 weeks of a moderate dietary salt alone diet.
  1. Methods: Interventions: All participants will be instructed to each 5-6 g of salt per day in their diet. In the moderate dietary salt plus additional salt arm, participants will receive blinded capsules that contain 6g of salt per day (12x 500g slow- release capsules). They will take 2g of salt 3 times per day. Participants in the placebo arm will receive blinded capsules that contain 6g of microcrystalline cellulose. Protocol compliance will be assessed with 24h urine sodium.

Randomization: This is a blinded cross-over study. The investigators will randomize patients to start with either salt capsules or placebo. After the 6-week study arm, participants will cross-over to the second study arm.

Study Visit Schedule: The study will consist of three in-house study sessions: a baseline assessment, and an assessment at the end of each study arm: moderate dietary salt plus additional salt and placebo. The baseline visit will serve as a screening visit. Each study session will take place over 1 day in the Autonomic Lab at the University of Calgary. There will also be four 24hr urine sodium collections, and multiple online REDCap surveys.

In-Lab Evaluation: The in-lab evaluation sessions while consist of autonomic function testing including a 10-minute tilt test, blood volume assessment, and supine and standing bloodwork. An IV will be started for the blood work.

Urine Sodium: Participants will complete a 24-hr urine sodium test around the time of each in-lab evaluation, as well as before the 1 week study wash in.

Study Surveys: At each assessment point (baseline and end of each arm), the investigators will send participants a secure REDCap survey link. At the end of the study, participants will also receive a patient experience survey. Participants will receive a total of 4 surveys.

Being tested
Sodium Chloride Capsules, Microcystalline Cellulose Capsules
Keywords
Sodium, Salt, Treatment
Medical subject headings
Postural Orthostatic Tachycardia Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sodium Chloride CapsulesDietary supplement

    Table salt in slow release capsules.

  • Microcystalline Cellulose CapsulesOther

    Microcrystalline Cellulose Capsules (Placebo)

Study groups in NCT05924646
Study groupRoleWhat they receive
Moderate Dietary Salt Plus Additional SaltExperimental6 grams of salt in slow release capsules combined with 6 grams of salt in the diet.
Receives: Dietary Supplement: Sodium Chloride Capsules
Moderate Dietary Salt AlonePlacebo comparator6 grams of microcrystalline cellulose in slow release capsules combined with 6 grams of salt in the diet.
Receives: Other: Microcystalline Cellulose Capsules

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Upright Heart Rate

    Upright heart rate measured during the tilt table test at the end of the moderate dietary salt plus additional salt arm compared to the tilt table test at the end of the moderate dietary salt alone arm

    Measured: 10 Minutes

Secondary outcomes (4)
  1. Vanderbilt Orthostatic Symptom Score (VOSS)

    VOSS score measured during the tilt table test at the end of the moderate dietary salt plus additional salt arm compared to the tilt table test at the end of the moderate dietary salt alone arm

    Measured: 10 Minutes

  2. Systolic Blood Pressure

    Upright systolic blood pressure measured during the tilt table test at the end of the moderate dietary salt plus additional salt arm compared to the tilt table test at the end of the moderate dietary salt alone arm

    Measured: 10 Minutes

  3. Diastolic Blood Pressure

    Upright systolic blood pressure measured during the tilt table test at the end of the moderate dietary salt plus additional salt arm compared to the tilt table test at the end of the moderate dietary salt alone arm

    Measured: 10 minutes

  4. Stroke volume

    Upright stroke volume measured during the tilt table test at the end of the moderate dietary salt plus additional salt arm compared to the tilt table test at the end of the moderate salt alone arm

    Measured: 10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jun 2023
  2. Study start7 May 2024
  3. Primary completion30 Jun 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Randomized cross-over trial with two arms: high salt and normal salt (placebo).
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05924646
Sponsor's protocol ID
REB23-0779
Acronym
CASA-POTS
Status last verified
Apr 2026
First submitted
20 Jun 2023
Last updated
7 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Sodium Chloride Capsules and Microcystalline Cellulose Capsules in people with Postural Orthostatic Tachycardia Syndrome, run by University of Calgary at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Satish R Raj, MD MSCI (4032106152, autonomic.research@ucalgary.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Upright Heart Rate (time frame: 10 Minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in